Analysis on Ethical Issues in Off-label Use of Antitumor Drugs
10.12026/j.issn.1001-8565.2023.07.02
- VernacularTitle:抗肿瘤药物超说明书使用面临的伦理问题探析
- Author:
Lei ZHANG
1
;
Wenbing MA
1
,
2
;
Pengfei SONG
1
;
Ting WANG
1
Author Information
1. Dispensary for Inpatients of Pharmacy Department, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
2. School of Life Science and Technology, Xi’an Jiaotong University, Xi’an 710049, China
- Publication Type:Journal Article
- Keywords:
Antitumor Drug;
Off-label Use;
Informed Consent;
Ethical Issues
- From:
Chinese Medical Ethics
2023;36(7):714-717
- CountryChina
- Language:Chinese
-
Abstract:
The phenomenon of off-label use of antitumor drugs in the treatment of malignant tumors is relatively common. Although it is conducive to the development of clinical medical practice, but it is still necessary to pay attention to ethical issues such as medication risks and inadequate implementation of informed consent. Therefore, to effectively avoid ethical risks and standardize the rational use of off-label antitumor drugs, this paper proposed that pharmacists should actively participate in the process of off-label use of antitumor drugs, improve the evidence level of evidence-based medicine, implement patients’ right to informed consent, and improve the hospital’s supervision system of off-label drug use, so as to ensure the reasonable and legal use of drugs by patients.
